Effect of Low Dose Metronomic Chemotherapy in Metastatic Breast Cancer (METRO)
Effect of Low Dose Metronomic Chemotherapy in Metastatic Breast Cancer - a Two Step Study With a Retrospective Analyses Followed by a Translational Phase II Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Karolina Larsson, Physician
- Phone Number: +4631-3421000
- Email: karolina.f.larsson@vgregion.se
Study Contact Backup
- Name: Barbro Linderholm, Associate Proffessor
- Phone Number: +4631-3421000
Study Locations
-
-
Vastra Gotaland
-
Goteborg, Vastra Gotaland, Sweden, 405 83
- Sahlgrenska University Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Written and informed consent
- Breast cancer confirmed by histology
- Recurrence (local or distant) not possible to cure
- Measurable or evaluable disease
- Life expectancy of more than tree months
- ECOG (Eastern Cooperative Oncology Group) performance 0-2
- No or any lines of previous therapies for recurrent disease.
- Adequate contraception for patients of Child bearing age.
Exclusion Criteria:
- Clinically significant cardiovascular disease
- Non healing wound, Active peptic ulcer or bone fracture
- Evidence of any other disease that puts the patient at high risk for treatment-related complications
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Overall response rates
Time Frame: From baseline until three months after last dose.
|
Radiological and Clinical evaluation
|
From baseline until three months after last dose.
|
|
Clinical benefit defined as the proportion of patients with CR(complete respons) or PR(partial respons) and patients with stable disease for 24 weeks or more.
Time Frame: 24 weeks
|
Complete response and Partial response
|
24 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Progression free survival
Time Frame: From baseline until three months after last dose.
|
Radiological and Clinical evaluation
|
From baseline until three months after last dose.
|
|
Overall survival
Time Frame: From baseline until death of any course assesed up to one year.
|
Death
|
From baseline until death of any course assesed up to one year.
|
|
Tolerance and safety assessment
Time Frame: From baseline until three months after last dose.
|
Clinical evaluation
|
From baseline until three months after last dose.
|
|
Health-related quality of life
Time Frame: From baseline until three months after last dose.
|
EORTC-QLQ (Quality of Life Questionnaire)-30
|
From baseline until three months after last dose.
|
|
Evaluation of molecular characteristics in ctDNA (circulating tumor) defined as mutational changes.
Time Frame: From baseline until the date of first documented progression or date of death from any cause, whichever came first.
|
Blood sample
|
From baseline until the date of first documented progression or date of death from any cause, whichever came first.
|
|
Evaluation of CA (cancer associated antigen) 15-3 in relation to treatment effect
Time Frame: From baseline until the date of first documented progression or date of death from any cause, whichever came first.
|
Blood sample
|
From baseline until the date of first documented progression or date of death from any cause, whichever came first.
|
|
Evaluation of immune deficiency panel markers defined as changes in immune cell composition
Time Frame: From baseline until the date of first documented progression or date of death from any cause, whichever came first.
|
Blood sample
|
From baseline until the date of first documented progression or date of death from any cause, whichever came first.
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
General Publications
- Masuda N, Lee SJ, Ohtani S, Im YH, Lee ES, Yokota I, Kuroi K, Im SA, Park BW, Kim SB, Yanagita Y, Ohno S, Takao S, Aogi K, Iwata H, Jeong J, Kim A, Park KH, Sasano H, Ohashi Y, Toi M. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. N Engl J Med. 2017 Jun 1;376(22):2147-2159. doi: 10.1056/NEJMoa1612645.
- Colleoni M, Rocca A, Sandri MT, Zorzino L, Masci G, Nole F, Peruzzotti G, Robertson C, Orlando L, Cinieri S, de BF, Viale G, Goldhirsch A. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol. 2002 Jan;13(1):73-80. doi: 10.1093/annonc/mdf013.
- Dellapasqua S, Bertolini F, Bagnardi V, Campagnoli E, Scarano E, Torrisi R, Shaked Y, Mancuso P, Goldhirsch A, Rocca A, Pietri E, Colleoni M. Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J Clin Oncol. 2008 Oct 20;26(30):4899-905. doi: 10.1200/JCO.2008.17.4789. Epub 2008 Sep 15.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms
- Neoplasms by Site
- Breast Diseases
- Breast Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antirheumatic Agents
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Cyclophosphamide
- Capecitabine
Other Study ID Numbers
Other Study ID Numbers
- 2018-09-20 Version 1.2
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.